Literature DB >> 19139811

Excision of pre-ulcerative forms of Buruli ulcer disease: a curative treatment?

K-H Herbinger1, D Brieske, J Nitschke, V Siegmund, W Thompson, E Klutse, N Y Awua-Boateng, E Bruhl, L Kunaa, M Schunk, O Adjei, T Löscher, G Bretzel.   

Abstract

BACKGROUND: Previous investigations have revealed that Mycobacterium ulcerans is extensively distributed spatially throughout ulcerative lesions, including in the margins of excised tissue. In contrast, bacilli in pre-ulcerative lesions are assumed to be concentrated in the center of the lesion. In order to assess the extent to which the surgical excision of pre-ulcerative lesions is capable of removing all infected tissue, we subjected the excision margins of pre-ulcerative lesions to laboratory analysis. PATIENTS AND METHODS: Eleven patients with laboratory-confirmed pre-ulcerative lesions were included in the study. The diameter of the lesion and excised tissue and the "surgical distance" between the border of the lesion and excision margin were measured. The entire excision margin was cut into segments and subjected to IS2404 PCR.
RESULTS: The results from the PCR analysis on the samples of excision margins were highly significantly associated with the surgical distance (p < 0.001). The margin samples of nodules were significantly more often PCR positive than the plaques (p = 0.025). The size of the lesion and the size of the excised tissue did not significantly influence the PCR results. Statistically, a surgical distance of more than 9 mm was found to reduce the risk of remaining infected tissue to less than 10%, that of 13 mm to reduce the risk to less than 5%, and that of 25 mm to reduce the risk to nearly 0%.
CONCLUSION: The results of this study show that in preulcerative Buruli ulcer disease, bacilli may extend beyond the actual size of the lesion and that there is a strong correlation between the presence of M. ulcerans in the margin samples and the surgical distance. Excision with a surgical distance of 25 mm avoided the risk of remaining mycobacteria in this study. However, no recurrences occurred in the patients with M. ulcerans-positive excision margins. The need of postoperative antimycobacterial treatment in these patients remains to be determined.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19139811     DOI: 10.1007/s15010-008-8073-4

Source DB:  PubMed          Journal:  Infection        ISSN: 0300-8126            Impact factor:   3.553


  16 in total

1.  A stepwise approach to the laboratory diagnosis of Buruli ulcer disease.

Authors:  G Bretzel; V Siegmund; J Nitschke; K H Herbinger; W Thompson; E Klutse; K Crofts; W Massavon; S Etuaful; R Thompson; K Asamoah-Opare; P Racz; F Vloten; C van Berberich; T Kruppa; E Ampadu; B Fleischer; O Adjei
Journal:  Trop Med Int Health       Date:  2007-01       Impact factor: 2.622

2.  Mycobacterium ulcerans infection (Buruli or Bairnsdale ulcer): challenges in developing management strategies.

Authors:  Kingsley Asiedu; Mark Wansbrough-Jones
Journal:  Med J Aust       Date:  2007-01-15       Impact factor: 7.738

3.  Outcomes for Mycobacterium ulcerans infection with combined surgery and antibiotic therapy: findings from a south-eastern Australian case series.

Authors:  Daniel P O'Brien; Andrew J Hughes; Allen C Cheng; Margaret J Henry; Peter Callan; Anthony McDonald; Ian Holten; Mike Birrell; John M Sowerby; Paul D R Johnson; Eugene Athan
Journal:  Med J Aust       Date:  2007-01-15       Impact factor: 7.738

4.  Mycobacterium ulcerans ulcers: a proposed surgical management algorithm.

Authors:  Laura Chin-Lenn; David Ying; James Leong; David Ross; Terry Wu; Simon Nazaretian; Simon Donahoe; Ram Silfen
Journal:  Ann Plast Surg       Date:  2006-07       Impact factor: 1.539

5.  Effectiveness of excision of pre-ulcerative Buruli lesions in field situations in a rural district in Ghana.

Authors:  G Amofah; S Asamoah; C Afram-Gyening
Journal:  Trop Doct       Date:  1998-04       Impact factor: 0.731

6.  Efficacy of the combination rifampin-streptomycin in preventing growth of Mycobacterium ulcerans in early lesions of Buruli ulcer in humans.

Authors:  S Etuaful; B Carbonnelle; J Grosset; S Lucas; C Horsfield; R Phillips; M Evans; D Ofori-Adjei; E Klustse; J Owusu-Boateng; G K Amedofu; P Awuah; E Ampadu; G Amofah; K Asiedu; M Wansbrough-Jones
Journal:  Antimicrob Agents Chemother       Date:  2005-08       Impact factor: 5.191

7.  What does detection of Mycobacterium ulcerans DNA in the margin of an excised Buruli ulcer lesion tell us?

Authors:  Simona Rondini; Ernestina Mensah-Quainoo; Thomas Junghanss; Gerd Pluschke
Journal:  J Clin Microbiol       Date:  2006-08-23       Impact factor: 5.948

8.  Identification and characterization of IS2404 and IS2606: two distinct repeated sequences for detection of Mycobacterium ulcerans by PCR.

Authors:  T Stinear; B C Ross; J K Davies; L Marino; R M Robins-Browne; F Oppedisano; A Sievers; P D Johnson
Journal:  J Clin Microbiol       Date:  1999-04       Impact factor: 5.948

9.  Post-surgical assessment of excised tissue from patients with Buruli ulcer disease: progression of infection in macroscopically healthy tissue.

Authors:  G Bretzel; V Siegmund; P Racz; F van Vloten; F Ngos; W Thompson; P Biason; O Adjei; B Fleischer; J Nitschke
Journal:  Trop Med Int Health       Date:  2005-11       Impact factor: 2.622

10.  [Epidemiologicl aspects of Buruli ulcer in Côte d'Ivoire: results of a national survey].

Authors:  J M Kanga; E D Kacou
Journal:  Bull Soc Pathol Exot       Date:  2001-03
View more
  5 in total

1.  High antibody titres induced by protein subunit vaccines using Mycobacterium ulcerans antigens Hsp18 and MUL_3720 with a TLR-2 agonist fail to protect against Buruli ulcer in mice.

Authors:  Kirstie M Mangas; Nicholas J Tobias; Estelle Marion; Jérémie Babonneau; Laurent Marsollier; Jessica L Porter; Sacha J Pidot; Chinn Yi Wong; David C Jackson; Brendon Y Chua; Timothy P Stinear
Journal:  PeerJ       Date:  2020-08-07       Impact factor: 2.984

2.  Cellular immunity confers transient protection in experimental Buruli ulcer following BCG or mycolactone-negative Mycobacterium ulcerans vaccination.

Authors:  Alexandra G Fraga; Teresa G Martins; Egídio Torrado; Kris Huygen; Françoise Portaels; Manuel T Silva; António G Castro; Jorge Pedrosa
Journal:  PLoS One       Date:  2012-03-08       Impact factor: 3.240

3.  Effectiveness of routine BCG vaccination on buruli ulcer disease: a case-control study in the Democratic Republic of Congo, Ghana and Togo.

Authors:  Richard Odame Phillips; Delphin Mavinga Phanzu; Marcus Beissner; Kossi Badziklou; Elysée Kalundieko Luzolo; Fred Stephen Sarfo; Wemboo Afiwa Halatoko; Yaw Amoako; Michael Frimpong; Abass Mohammed Kabiru; Ebekalisai Piten; Issaka Maman; Bawimodom Bidjada; Adjaho Koba; Koffi Somenou Awoussi; Basile Kobara; Jörg Nitschke; Franz Xaver Wiedemann; Abiba Banla Kere; Ohene Adjei; Thomas Löscher; Bernhard Fleischer; Gisela Bretzel; Karl-Heinz Herbinger
Journal:  PLoS Negl Trop Dis       Date:  2015-01-08

4.  Spontaneous clearance of a secondary Buruli ulcer lesion emerging ten months after completion of chemotherapy--a case report from Togo.

Authors:  Marcus Beissner; Ebekalisai Piten; Issaka Maman; Dominik Symank; Moritz Jansson; Jörg Nitschke; Komi Amekuse; Basil Kobara; Franz Wiedemann; Harald Hoffmann; Adolf Diefenhardt; Kossi Badziklou; Abiba Banla Kere; Thomas Löscher; Gisela Bretzel
Journal:  PLoS Negl Trop Dis       Date:  2012-07-31

5.  Implementation of a national reference laboratory for Buruli ulcer disease in Togo.

Authors:  Marcus Beissner; Kristina Lydia Huber; Kossi Badziklou; Wemboo Afiwa Halatoko; Issaka Maman; Felix Vogel; Bawimodom Bidjada; Koffi Somenou Awoussi; Ebekalisai Piten; Kerstin Helfrich; Carolin Mengele; Jörg Nitschke; Komi Amekuse; Franz Xaver Wiedemann; Adolf Diefenhardt; Basile Kobara; Karl-Heinz Herbinger; Abiba Banla Kere; Mireille Prince-David; Thomas Löscher; Gisela Bretzel
Journal:  PLoS Negl Trop Dis       Date:  2013-01-24
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.